

Special Issue

Diagnostic Imaging of Cancers: Role of PET/CT

Message from the Guest Editor

Positron emission tomography (PET) is becoming increasingly relevant for the diagnostic imaging of cancers. The value of already clinically available tracers, such as ^{18}F -FDG, ^{18}F -, and ^{68}Ga -PSMA ligands, or ^{68}Ga -DOTATOC/DOTATAE, is increasingly recognized by clinicians, and PET imaging plays an emerging role for the workup of various cancers. On the other hand, new PET tracer molecules, including fibroblast activation protein inhibitors (FAPI tracers), estrogen receptor- or HER2-targeted imaging for breast cancer, or CXCR4-targeted imaging of hematological malignancies, provide new insights into the molecular characteristics of cancers and offer new approaches for staging and therapy response evaluation. Beyond new tracers, new PET scanners with markedly increased fields of views allow fast dynamic and parametric imaging of the whole body and are expected to radically change the clinical setting of oncological PET imaging. In this Special Issue of *Cancers*, we welcome original scientific contributions that focus on innovative clinical and preclinical approaches for the PET imaging of cancers.

Guest Editor

Dr. Manuel Röhrich

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), D-68120 Heidelberg, Germany

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130433

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)